FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. HC Wainwright raised FibroGen to a “strong-buy” rating in a report on Tuesday, December 17th. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.55 on Wednesday. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.93. The stock’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.52. The firm has a market cap of $55.00 million, a price-to-earnings ratio of -0.44 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period in the previous year, the business posted ($0.52) EPS. As a group, research analysts predict that FibroGen will post -0.86 EPS for the current year.

Institutional Trading of FibroGen

Several institutional investors have recently modified their holdings of FGEN. Point72 DIFC Ltd boosted its position in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares in the last quarter. Doheny Asset Management CA purchased a new stake in FibroGen during the second quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of FibroGen in the 2nd quarter valued at approximately $130,000. Sei Investments Co. boosted its position in shares of FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in FibroGen during the 2nd quarter worth about $145,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.